277 related articles for article (PubMed ID: 35090028)
1. Approach to the Patient With Treatment-resistant Acromegaly.
Coopmans EC; van der Lely AJ; Neggers SJCMM
J Clin Endocrinol Metab; 2022 May; 107(6):1759-1766. PubMed ID: 35090028
[TBL] [Abstract][Full Text] [Related]
2. Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study.
Chiloiro S; Bima C; Tartaglione T; Giampietro A; Gessi M; Lauretti L; Anile C; Colosimo C; Rindi G; Pontecorvi A; De Marinis L; Bianchi A
J Clin Endocrinol Metab; 2019 Nov; 104(11):5478-5482. PubMed ID: 31219586
[TBL] [Abstract][Full Text] [Related]
3. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.
Feelders RA; Hofland LJ; van Aken MO; Neggers SJ; Lamberts SW; de Herder WW; van der Lely AJ
Drugs; 2009 Nov; 69(16):2207-26. PubMed ID: 19852525
[TBL] [Abstract][Full Text] [Related]
4. Current and future medical treatments for patients with acromegaly.
Maffezzoni F; Formenti AM; Mazziotti G; Frara S; Giustina A
Expert Opin Pharmacother; 2016 Aug; 17(12):1631-42. PubMed ID: 27352098
[TBL] [Abstract][Full Text] [Related]
5. Current therapy and drug pipeline for the treatment of patients with acromegaly.
Kumar SS; Ayuk J; Murray RD
Adv Ther; 2009 Apr; 26(4):383-403. PubMed ID: 19444656
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
7. Second line treatment of acromegaly: Pasireotide or Pegvisomant?
Chiloiro S; Bianchi A; Giampietro A; Pontecorvi A; Raverot G; Marinis L
Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101684. PubMed ID: 35931640
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline in acromegaly.
Kuhn E; Chanson P
Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
[TBL] [Abstract][Full Text] [Related]
9. [Role of somatostatin receptor ligands in the treatment of acromegaly--literature review].
Nemes O; Mezosi E
Orv Hetil; 2011 May; 152(18):715-21. PubMed ID: 21498160
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.
Ciresi A; Radellini S; Guarnotta V; Giordano C
BMC Endocr Disord; 2018 Jan; 18(1):2. PubMed ID: 29361932
[TBL] [Abstract][Full Text] [Related]
11. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response.
Chiloiro S; Giampietro A; Mirra F; Donfrancesco F; Tartaglione T; Mattogno PP; Angelini F; Liverana L; Gessi M; Carmelo A; Rindi G; Giustina A; Fleseriu M; Pontecorvi A; De Marinis L; Bianchi A
Eur J Endocrinol; 2021 Feb; 184(2):217-229. PubMed ID: 33136550
[TBL] [Abstract][Full Text] [Related]
12. [Growth hormone receptor antagonist in the treatment of acromegaly].
Hubina E; Tóth A; Kovács GL; Dénes J; Kovács L; Góth M
Orv Hetil; 2011 May; 152(18):709-14. PubMed ID: 21498159
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of pituitary adenomas].
Mezosi E; Nemes O
Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
[TBL] [Abstract][Full Text] [Related]
15. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
16. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients.
Neggers SJ; de Herder WW; Feelders RA; van der Lely AJ
Pituitary; 2011 Sep; 14(3):253-8. PubMed ID: 21221818
[TBL] [Abstract][Full Text] [Related]
17. [Outcome of somatostatin analogue treatment in acromegaly].
Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
19. Pasireotide in the Personalized Treatment of Acromegaly.
Puig-Domingo M; Bernabéu I; Picó A; Biagetti B; Gil J; Alvarez-Escolá C; Jordà M; Marques-Pamies M; Soldevila B; Gálvez MA; Cámara R; Aller J; Lamas C; Marazuela M
Front Endocrinol (Lausanne); 2021; 12():648411. PubMed ID: 33796079
[TBL] [Abstract][Full Text] [Related]
20. Medical treatment of acromegaly-experience from the Croatian acromegaly registry.
Solak M; Kraljević I; Popovac H; Šambula L; Polovina TŠ; Balaško A; Tomšić KZ; Dušek T; Novak A; Tripolski M; Kaštelan D
Endocrine; 2023 Sep; 81(3):555-561. PubMed ID: 37389718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]